To determine the clinical feasibility of combined MDM2 and MEK inhibition in colorectal and thyroid cancers, we assessed the TP53 WT status and the presence of MAPK alterations (i.e., KRAS, BRAF, NRAS) using the cBioportal database (Source of data: The Cancer Genome Atlas, Memorial Sloan Kettering Cancer Center, Genentech, Clinical Proteomic Tumor Analysis Consortium 2.0, Case Comprehensive Cancer Center for CRC and The Cancer Genome Atlas for PTC)33. This evidence concerns the gene KRAS and colorectal carcinoma.